UTAH STATE UNIVERSITY - TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT USING ASSAYS SUCH AS CPE TO DETERMINE EC50; ASSAYS SUCH AS VYR/PR TO DETERMINE EC90, AND CYTOTOXICITY (CC50) OF EXPERIMENTAL COMPOUNDS AGAINST VIRUSES THAT REQUIRE A MAXIMUM BIOSAFETY LABORATORY CONTAINMEN

PIID: 75N93026F00001Solicitation ID: B28

Signed Date: Jan 7, 2026Effective Date: Jan 9, 2026End Date: Closes in 72 days

Award $

$419K

Vendor

UTAH STATE UNIVERSITY

NAICS

541714

Signed Date

Jan 7, 2026

Key Details

Dollars Obligated

$418,905

Base & All Options

$793,243

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

National Institutes of Health

NAICS Code

541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Product Service Code

AN11 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

LOGAN, UT, 843221415, CD-UT-01

Description

TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT USING ASSAYS SUCH AS CPE TO DETERMINE EC50; ASSAYS SUCH AS VYR/PR TO DETERMINE EC90, AND CYTOTOXICITY (CC50) OF EXPERIMENTAL COMPOUNDS AGAINST VIRUSES THAT REQUIRE A MAXIMUM BIOSAFETY LABORATORY CONTAINMEN

Context & Analysis

On Jan 7, 2026, Department of Health and Human Services obligated $418,905 to UTAH STATE UNIVERSITY for to determine the antiviral inhibitory effect using assays such as cpe to determine ec50; assays such as vyr/pr to determine ec90, and cytotoxicity (cc50) of experimental compounds against viruses that…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 2 offers received. Performance is located in LOGAN, UT. The contract is scheduled through Jan 8, 2027 — approximately 2 months remaining.